Aesculus Bio ApS: Financial statements 2024
CVR: 40560866
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Aesculus Bio ApS (CVR 40560866) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -49,785 and a net result of DKK -45,866 compared with DKK -10,881 the year before. Equity in the 2024 report amounted to DKK 95,340. The solvency ratio was 41.7%.
- Gross Profit
- DKK -49,785
- Profit/Loss
- DKK -45,866
- Equity
- DKK 95,340
- Total Assets
- DKK 228,405
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -50 t. | -46 t. | 95 t. | - |
| 2023 | - | -14 t. | -11 t. | 141 t. | - |
| 2022 | - | -25 t. | -15 t. | 152 t. | - |
| 2021 | - | 88 t. | 74 t. | 167 t. | - |
| 2020 | - | -12 t. | -15 t. | 93 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Aesculus Bio ApS has published its annual report for 2023. Gross profit came to DKK -13,631, and the net result was DKK -10,881.
About Aesculus Bio ApS
Aesculus Bio ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2019. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Benjamin Anderschou Holbech Jensen. The board consists of Peter Hviid Nordkild (chair) and Benjamin Anderschou Holbech Jensen. The company is owned by Benjamin Anderschou Holbech Jensen, PN INVESTMENT ApS and Jan Wehkamp. In 2025, the company reported a gross profit of DKK -154,862 and a net result of DKK -129,437 compared with DKK -45,866 the year before. Equity in the 2025 report amounted to DKK -34,097.